Boston Partners’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-561,942
| Closed | -$19.4M | – | 749 |
|
|
2024
Q1 | $19.4M | Buy |
+561,942
| New | +$22.5M | 0.02% | 330 |
|
|
2020
Q2 | – | Sell |
-13,001
| Closed | -$581K | – | 675 |
|
|
2020
Q1 | $581K | Buy |
13,001
+128
| +1% | +$6.72K | ﹤0.01% | 585 |
|
|
2019
Q4 | $750K | Sell |
12,873
-246
| -2% | -$14.6K | ﹤0.01% | 607 |
|
|
2019
Q3 | $788K | Hold |
13,119
| – | – | ﹤0.01% | 605 |
|
|
2019
Q2 | $733K | Buy |
13,119
+171
| +1% | +$8.81K | ﹤0.01% | 628 |
|
|
2019
Q1 | $721K | Sell |
12,948
-7,792
| -38% | -$397K | ﹤0.01% | 642 |
|
|
2018
Q4 | $935K | Sell |
20,740
-230,443
| -92% | -$12.6M | ﹤0.01% | 659 |
|
|
2018
Q3 | $16.5M | Sell |
251,183
-5,395
| -2% | -$335K | 0.02% | 339 |
|
|
2018
Q2 | $16.5M | Buy |
256,578
+2,723
| +1% | +$169K | 0.02% | 346 |
|
|
2018
Q1 | $14M | Sell |
253,855
-146,441
| -37% | -$7.68M | 0.02% | 352 |
|
|
2017
Q4 | $19.2M | Buy |
400,296
+28,408
| +8% | +$1.39M | 0.02% | 325 |
|
|
2017
Q3 | $18.8M | Sell |
371,888
-207,447
| -36% | -$10.7M | 0.02% | 322 |
|
|
2017
Q2 | $31.6M | Sell |
579,335
-173,810
| -23% | -$8.3M | 0.04% | 272 |
|
|
2017
Q1 | $31.7M | Sell |
753,145
-3,425
| -0.5% | -$146K | 0.04% | 267 |
|
|
2016
Q4 | $32.5M | Sell |
756,570
-66,152
| -8% | -$2.69M | 0.04% | 263 |
|
|
2016
Q3 | $34M | Sell |
822,722
-10,374
| -1% | -$435K | 0.05% | 258 |
|
|
2016
Q2 | $33.2M | Sell |
833,096
-93,222
| -10% | -$3.35M | 0.05% | 247 |
|
|
2016
Q1 | $31.2M | Buy |
926,318
+9,286
| +1% | +$289K | 0.05% | 257 |
|
|
2015
Q4 | $31.1M | Buy |
917,032
+46,786
| +5% | +$1.46M | 0.04% | 250 |
|
|
2015
Q3 | $25.9M | Sell |
870,246
-174,424
| -17% | -$5.45M | 0.04% | 258 |
|
|
2015
Q2 | $28.8M | Buy |
1,044,670
+128,483
| +14% | +$3.42M | 0.04% | 256 |
|
|
2015
Q1 | $23.1M | Sell |
916,187
-38,248
| -4% | -$904K | 0.03% | 280 |
|
|
2014
Q4 | $21.2M | Sell |
954,435
-44,156
| -4% | -$895K | 0.03% | 294 |
|
|
2014
Q3 | $20.3M | Sell |
998,591
-1,473,124
| -60% | -$29.3M | 0.03% | 282 |
|
|
2014
Q2 | $47.5M | Sell |
2,471,715
-1,027,493
| -29% | -$19.1M | 0.08% | 205 |
|
|
2014
Q1 | $65.8M | Buy |
3,499,208
+56,303
| +2% | +$1.09M | 0.12% | 174 |
|
|
2013
Q4 | $67.1M | Sell |
3,442,905
-100,443
| -3% | -$1.84M | 0.14% | 157 |
|
|
2013
Q3 | $58.3M | Buy |
3,543,348
+71,949
| +2% | +$1.15M | 0.14% | 157 |
|
|
2013
Q2 | $52M | Buy |
+3,471,399
| New | +$50.9M | 0.14% | 151 |
|
Other funds holding IART
CB
Boston Partners's IART Position: Q2 2024 in Review
Boston Partners sold out of Integra LifeSciences (IART) in Q2 2024, closing a stake of 561,942 shares — an estimated $19.4M sold.
Boston Partners first reported a position in IART in Q2 2013 and held it in 29 quarters. The position peaked at $67.1M in Q4 2013. 238 funds tracked by Wall St. Rank hold IART as of Q2 2024.
- Boston Partners reported no remaining Integra LifeSciences position as of Q2 2024 after selling out during the quarter.
- Boston Partners sold 561,942 Integra LifeSciences shares in Q2 2024, an estimated $19.4M.
- Boston Partners first reported a position in Integra LifeSciences in Q2 2013 and held it in 29 quarters.
- Boston Partners's Integra LifeSciences position peaked at $67.1M in Q4 2013.
- 238 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2024.
Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.